C3 and paroxysmal nocturnal hemoglobinuria: Pegcetacoplan (C3 inhibitor) was recently approved by the FDA for paroxysmal nocturnal hemoglobinuria, in addition to avacopan (C5a receptor antagonist) for ANCA-associated vasculitis.